Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CIK Cells Combined with Chemotherapy in de novo AML
ChiCTR-OIC-16008430Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic cytokine-induced killer cells in acute myeloid leukemia (AML), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Safety and efficacy. Started Jun 2015; status: recruiting.
02
Drugs
allogeneic cytokine-induced killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OIC-16008430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008430.